GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses

O. Bruno, E. Fedele, J. Prickaerts, L. A. Parker, E. Canepa, Chiara Brullo, A. Cavallero, Elena Gardella, A. Balbi, C. Domenicotti, E. Bollen, Hieronymus J. M. Gijselaers, T. Vanmierlo, K. Erb, C. L. Limebeer, F. Argellati, U. M. Marinari, Maria Adelaide Pronzato, R. Ricciarelli*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


BACKGROUND AND PURPOSE Strategies designed to enhance cerebral cAMP have been proposed as symptomatic treatments to counteract cognitive deficits. However, pharmacological therapies aimed at reducing PDE4, the main class of cAMP catabolizing enzymes in the brain, produce severe emetic side effects. We have recently synthesized a 3-cyclopentyloxy-4-methoxybenzaldehyde derivative, structurally related to rolipram, and endowed with selective PDE4D inhibitory activity. The aim of the present study was to investigate the effect of the new drug, namely GEBR-7b, on memory performance, nausea, hippocampal cAMP and amyloid-beta (A beta) levels.
Original languageEnglish
Pages (from-to)2054-2063
JournalBritish Journal of Pharmacology
Issue number8
Publication statusPublished - Dec 2011


  • PDE4 inhibitor
  • memory
  • phosphodiesterase
  • cyclic AMP
  • rolipram
  • emesis

Cite this